A Study on a New Staining Method (C4d Staining) of Transplanted Kidney Biopsies

Patients who had received kidney transplantation may suffer from rejection. Recently, positive staining for C4d in kidney biopsies of malfunctioning transplant kidney is increasingly recognized as an important prognostic indicator of poorer long-term kidney outcome. Data is, however, lacking in Hong Kong.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Kidney Transplantation Graft Rejection

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Princess Margaret Hospital

Hong Kong, China

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

All renal allograft biopsies performed in Princess Margaret Hospital (PMH) during the period 1st April 2003 to 31st August 2005 for unexplained acute renal dysfunction (Creatinine rise from baseline by ≥ 20%) or delayed graft function in the immediate post-transplantation period were included in the study. Both cadaveric and living-donor transplant allografts were included.

Exclusion criteria

patients who were < 18 years' old at the time of renal biopsy or whose records were so incomplete that preclude meaningful analysis

Treatment and study plan

Renal Biopsy

Procedure

Sponsors and collaborators

Lead sponsor

Hospital Authority, Hong Kong

Other Gov

Registry information

Official study title

Experience of C4d Staining in Renal Allograft Biopsies

Important dates

Study start: 2006
Study completion: 2006
First posted: Jul 9, 2007
Registry last updated: Jun 16, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed